Lurasidone

Small molecule

Also known as SM-13496

Approvedregulatory verdict

Evidence outlook

Approved: Schizophrenia, Bipolar Depression

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (3)
JP
  • Treatment of schizophrenia and the improvement of depressive symptoms in patients with bipolar disorderPMDA
  • Schizophrenia and bipolar depressionsumitomo-pharma.com
Product first approved 2020
EU
  • Treatment of schizophrenia in adults aged 18 years and over.
Product first approved 2014EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (37)
Bipolar Depression
NCT01914393 · Sumitomo Pharma America, Inc.
2013-09-30 – 2018-10-17 · Schizophrenia, Autism, Bipolar Depression
What this study did
NCT01986101 · Sumitomo Pharma Co., Ltd.
2014-02-19 – 2017-02-16 · Bipolar Depression
What this study did
NCT00868959 · Sumitomo Pharma America, Inc.
2009-04 – 2013-02 · Bipolar Depression
What this study did
NCT01284517 · Sumitomo Pharma America, Inc.
2010-11 – 2012-08 · Bipolar Depression
What this study did
NCT00868452 · Sumitomo Pharma America, Inc.
2009-04 – 2012-01 · Bipolar Depression
What this study did
Schizophrenia
NCT01911429 · Sumitomo Pharma America, Inc.
2013-08 – 2015-12 · Schizophrenia
What this study did
NCT02002832 · Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
2013-12 – 2015-11 · Schizophrenia
What this study did
NCT01614912 · Sumitomo Pharma Co., Ltd.
2012-08 – 2015-05 · Schizophrenia
What this study did
NCT01614899 · Sumitomo Pharma Co., Ltd.
2012-07-02 – 2014-11-17 · Schizophrenia
What this study did
NCT01821378 · Sumitomo Pharma America, Inc.
2013-05 – 2014-06 · Schizophrenia
What this study did
NCT01485640 · Sumitomo Pharma America, Inc.
2011-06 – 2014-02 · Schizophrenia, Bipolar Disorder
What this study did
NCT01173874 · New York State Psychiatric Institute
2010-07 – 2013-11 · Schizophrenia
What this study did
NCT01566162 · Sumitomo Pharma America, Inc.
2012-04 – 2013-11 · Schizophrenia
What this study did
NCT01979679 · University of California, Irvine
2008-12 – 2013-10 · Schizophrenia
What this study did
NCT01435928 · Sumitomo Pharma America, Inc.
2011-09 – 2013-08 · Schizophrenia
What this study did
NCT01143090 · Sumitomo Pharma America, Inc.
2010-08 – 2011-11 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00789698 · Sumitomo Pharma America, Inc.
2008-12 – 2011-07 · Chronic Schizophrenia
What this study did
NCT01143077 · Sumitomo Pharma America, Inc.
2010-06 – 2011-05 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00641745 · Sumitomo Pharma America, Inc.
2008-03 – 2010-07 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00790192 · Sumitomo Pharma America, Inc.
2008-10 – 2010-07 · Schizophrenia
What this study did
NCT00711269 · Sumitomo Pharma Co., Ltd.
2008-06-27 – 2010-04-27 · Schizophrenia
What this study did
Other / comorbidity
NCT07781293 · Bukwang Pharmaceutical
2026-09-28 – 2027-10 · Major Depressive Disorder (MDD), Major Depressive Disorder With Psychotic Features
What this study did
NCT02731612 · Lakshmi N Yatham
2017-05-08 – 2024-12-31 · Bipolar Disorder
What this study did
NCT04383691 · Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
2020-12-11 – 2022-12-23 · Bipolar I Depression
What this study did
NCT01986114 · Sumitomo Pharma Co., Ltd.
2014-01-29 – 2018-02-17 · Bipolar I Disorder
What this study did
NCT02147379 · University of British Columbia
2014-05 – 2017-01-12 · Bipolar I Disorder
What this study did
NCT02046369 · Sumitomo Pharma America, Inc.
2014-03 – 2016-10 · Bipolar I Depression
What this study did
NCT01358357 · Sumitomo Pharma America, Inc.
2011-06 – 2015-04 · Bipolar I Disorder
What this study did
NCT01911442 · Sumitomo Pharma America, Inc.
2013-08 – 2014-11 · Autism
What this study did
NCT01421134 · Sumitomo Pharma America, Inc.
2011-09 – 2014-10 · Major Depressive Disorder With Mixed Features
What this study did
NCT01423253 · Sumitomo Pharma America, Inc.
2011-09 – 2013-10 · Major Depressive Disorder
What this study did
NCT01423240 · Sumitomo Pharma America, Inc.
2012-01 – 2012-12 · Major Depressive Disorder
What this study did
Phase 2/3 (1)
Bipolar Depression
NCT03402152 · NeuroRx, Inc.
2018-11-01 – 2021-06-01 · Bipolar Depression, Suicidal Ideation
What this study did
Phase 2 (6)
Bipolar Depression
NCT02974010 · NeuroRx, Inc.
2018-01-15 – 2019-11-20 · Bipolar Depression, Suicidal Ideas, Suicidal Ideation, Suicide, Attempted
What this study did
Schizophrenia
NCT01731119 · University of North Carolina, Chapel Hill
2012-12 – 2014-08 · Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychosis NOS, Autistic Disorder, Asperger Syndrome, Child Development Disorders, Pervasive, Bipolar I Disorder, Bipolar II Disorder, Mood Disorder NOS, Severe Major Depression With Psychotic Features, Single Episode Major Depression Without Psychotic Symptoms, Severe Mood Disorder With Psychotic Features
What this study did
NCT00088621 · Sumitomo Pharma America, Inc.
2004-07 – 2005-10 · Schizophrenia
What this study did
NCT00088634 · Sumitomo Pharma America, Inc.
2004-05 – 2004-12 · Schizophrenia
What this study did
NCT00044005 · Sumitomo Pharma America, Inc.
2002-09 – 2003-11 · Schizophrenia
What this study did
NCT00044044 · Sumitomo Pharma America, Inc.
2002-07 – 2003-05 · Schizophrenia
What this study did
Phase 1 (11)
Schizophrenia
NCT02174510 · Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
2014-03 – 2014-04 · Schizophrenia
What this study did
NCT02174523 · Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
2014-04 – 2014-04 · Schizophrenia
What this study did
NCT01620060 · Sumitomo Pharma America, Inc.
2012-06 – 2013-05 · Schizophrenia, Autism
What this study did
NCT01074632 · Sumitomo Pharma America, Inc.
2009-05 – 2009-09 · Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder
What this study did
NCT01082263 · Sumitomo Pharma America, Inc.
2008-10 – 2008-11 · Schizophrenia Patients
What this study did
NCT01074073 · Sumitomo Pharma America, Inc.
2008-08 – 2008-10 · Schizophrenia
What this study did
NCT01082289 · Sumitomo Pharma America, Inc.
2008-09 – 2008-10 · Schizophrenia
What this study did
NCT01082250 · Sumitomo Pharma America, Inc.
2008-07 – 2008-09 · Schizophrenia
What this study did
Other / comorbidity
NCT01082276 · Sumitomo Pharma America, Inc.
2008-08 – 2008-08 · Male, Healthy Normal Subjects
What this study did
NCT01082146 · Sumitomo Pharma America, Inc.
2008-08 – 2008-08 · Pharmacokinetics, Metabolism
What this study did
Phase 4 (11)
Bipolar Depression
NCT06433635 · Massachusetts General Hospital
2024-10-01 – 2030-02-28 · Bipolar I Disorder, Depression
What this study did
NCT03902613 · New York State Psychiatric Institute
2019-02-07 – 2019-08-01 · Bipolar Depression
What this study did
Schizophrenia
NCT05351736 · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
2022-01-26 – 2024-04-28 · Schizophrenia
What this study did
NCT05011669 · Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
2021-08-16 – 2023-06-16 · Schizophrenia
What this study did
NCT05213143 · Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
2021-12-30 – 2022-11-18 · Schizophrenia
What this study did
NCT03393026 · Standard Chem. & Pharm. Co., Ltd.
2018-01-03 – 2019-09-17 · Schizophrenia
What this study did
NCT03304457 · All India Institute of Medical Sciences, Bhubaneswar
2017-08-25 – 2018-03-25 · Schizophrenia
What this study did
NCT02199743 · University of Texas Southwestern Medical Center
2013-02 – 2016-06 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT01569659 · Northwestern University
2011-10 – 2015-07 · Schizophrenia
What this study did
Other / comorbidity
NCT07806227 · Martin Lan
2026-11-01 – 2028-07-30 · Bipolar Disorder Depression
What this study did
NCT01932541 · Massachusetts General Hospital
2017-01 – 2018-07 · Mania, Bipolar I, Bipolar II, Bipolar Spectrum Disorder, Bipolar Disorder
What this study did
Early phase / not applicable (2)
Bipolar Depression
NCT02239094 · New York State Psychiatric Institute
2015-01 – 2016-09 · Bipolar Depression
What this study did
Other / comorbidity
NCT05480150 · First Affiliated Hospital of Zhejiang University
2021-11-01 – 2026-12-31 · Major Depressive Disorder, Bipolar Disorder, Mixed, Affective; Disorder, Organic
What this study did
Used as active comparator (4)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Bipolar Depression
NCT03396068 · NeuroRx, Inc.
2019-12-01 – 2024-12-31 · Bipolar Depression, Suicidal Ideation
What this study did
Phase 2/3 (1)
Bipolar Depression
NCT03395392 · NeuroRx, Inc.
2022-05-12 – 2024-03-30 · Bipolar Depression, Suicidal Ideation and Behavior
What this study did
Phase 4 (2)
Schizophrenia
NCT02282085 · Matt Byerly
2014-12 – 2017-12 · Schizophrenia
What this study did
Other / comorbidity
NCT00806234 · Johns Hopkins University
2009-01 – 2014-03 · Psychotic Disorders
What this study did
Studied as part of a combination product (1)

Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.

Phase 2 (1)
Other / comorbidity
NCT06128213 · NeuroRx, Inc.
2024-03-31 – 2024-09-30 · Urinary Tract Infections, Pyelonephritis
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (1)
Schizophrenia
NCT03557931 · Astellas Pharma Global Development, Inc.
2018-07-13 – 2019-10-21 · Schizophrenia
What this study did

Competitive landscape

This mechanism is crowded: 25 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Bipolar Depression: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Lurasidone: this drugApprovedSmall moleculeDopamine D2/D3 receptor + 5-HT7 receptor, Dopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Cariprazine (Vraylar)ApprovedSmall moleculeDopamine D3/D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
Lumateperone (Caplyta)ApprovedSmall moleculeSerotonin 5-HT2A / dopamine D1-D2 receptornot yet gradedNo reviewed efficacy summary in this indication
D-Cycloserine / Lurasidone (NRX-101)Phase 3Small moleculeNMDA receptor (glycine site) + dopamine/5-HT receptornot yet gradedNo reviewed efficacy summary in this indication
ABBV-932
Phase 1(overall)
Small moleculeDopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Lurasidone to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Early phase / not applicableMajor Depressive Disorder, Bipolar Disorder, Mixed, Affective; Disorder, OrganicRecruiting
Est. primary completion 2026-12-31 · NCT05480150 · CT.gov ↗
What to watch
2027 (1)
October 2027 (1)
Phase 3Major Depressive Disorder (MDD), Major Depressive Disorder With Psychotic FeaturesNot yet recruiting
Est. primary completion 2027-10 · NCT07781293 · CT.gov ↗
What to watch
2028 (1)
July 2028 (1)
Phase 4Bipolar Disorder DepressionNot yet recruiting
Est. primary completion 2028-07-30 · NCT07806227 · CT.gov ↗
What to watch
2030 (1)
February 2030 (1)
Phase 4Bipolar DepressionActive not recruiting
Est. primary completion 2030-02-28 · NCT06433635 · CT.gov ↗
What to watch

See the full readout calendar ↗